Medical interventions for the prevention of platinum-induced hearing loss in children with cancer (Q24197812)

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Use of amifostine in the therapy of osteosarcoma in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Chemotherapy-induced chromosomal damage in peripheral blood lymphocytes of cancer patients supplemented with antioxidants or placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Calcium supplementation and ototoxicity in patients receiving cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Assessment of the effect of chemotherapy and radiotherapy on the auditory function of children with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Ototoxicity with cisplatin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Hearing loss in children receiving cisplatin chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Auditory late effects of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Preventing platinum-induced ototoxicity in children-is there a potential role for sodium thiosulfate?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Hepatoblastoma, cisplatin, and ototoxicity: good news on deaf ears

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Platinum Compound-Related Ototoxicity in Children: Long-Term Follow-Up Reveals Continuous Worsening of Hearing Loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Cisplatin ototoxicity in children: a practical grading system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Prevention of hearing loss in children receiving cisplatin chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Furosemide-Induced Ototoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Pediatric audiology: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Statistical considerations in the intent-to-treat principle

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Mechanisms of cisplatin-induced ototoxicity and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Cisplatin ototoxicity and protection: clinical and experimental studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Best practice in assessing ototoxicity in children with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009219.PUB2